Brown Advisory Inc. lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 684,396 shares of the medical research company’s stock after selling 86,523 shares during the quarter. Brown Advisory Inc. owned about 1.45% of Charles River Laboratories International worth $73,928,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in CRL. Lord Abbett & CO. LLC bought a new position in Charles River Laboratories International in the 2nd quarter worth $65,915,000. FMR LLC raised its holdings in Charles River Laboratories International by 23.8% in the 2nd quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after acquiring an additional 591,066 shares during the period. TimesSquare Capital Management LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth $35,182,000. FIL Ltd raised its holdings in Charles River Laboratories International by 325.4% in the 2nd quarter. FIL Ltd now owns 417,465 shares of the medical research company’s stock worth $42,227,000 after acquiring an additional 319,324 shares during the period. Finally, Koch Industries Inc. bought a new position in Charles River Laboratories International in the 2nd quarter worth $240,000. Hedge funds and other institutional investors own 96.24% of the company’s stock.

Charles River Laboratories International, Inc. (NYSE:CRL) traded up $1.54 during midday trading on Friday, reaching $104.20. 329,000 shares of the company’s stock traded hands, compared to its average volume of 379,413. The company has a quick ratio of 1.62, a current ratio of 1.88 and a debt-to-equity ratio of 1.13. The firm has a market cap of $4,896.71, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 1.65 and a beta of 0.94. Charles River Laboratories International, Inc. has a 52 week low of $69.51 and a 52 week high of $119.05.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million for the quarter, compared to analyst estimates of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the business posted $1.18 EPS. sell-side analysts forecast that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current year.

In other news, insider Davide Molho sold 6,165 shares of Charles River Laboratories International stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $110.00, for a total transaction of $678,150.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories International stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Over the last 90 days, insiders acquired 10,500 shares of company stock worth $2,885 and sold 1,012,147 shares worth $1,591,514. Company insiders own 2.20% of the company’s stock.

Several research analysts recently commented on the stock. SunTrust Banks reiterated a “buy” rating and issued a $113.00 target price on shares of Charles River Laboratories International in a report on Friday, November 17th. Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Robert W. Baird set a $117.00 price target on shares of Charles River Laboratories International and gave the stock a “buy” rating in a research report on Monday, November 13th. ValuEngine lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Finally, Bank of America decreased their price target on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Charles River Laboratories International presently has an average rating of “Buy” and an average target price of $106.63.

COPYRIGHT VIOLATION NOTICE: “Charles River Laboratories International, Inc. (CRL) Position Reduced by Brown Advisory Inc.” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/12/01/charles-river-laboratories-international-inc-crl-position-reduced-by-brown-advisory-inc.html.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.